Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2015', provides an overview of the Chemotherapy Induced Peripheral Neuropathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Peripheral Neuropathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chemotherapy Induced Peripheral Neuropathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chemotherapy Induced Peripheral Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chemotherapy Induced Peripheral Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chemotherapy Induced Peripheral Neuropathy Overview 8
Therapeutics Development 9
Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Overview 9
Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis 10
Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Development by Companies 11
Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes 13
Chemotherapy Induced Peripheral Neuropathy - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Chemotherapy Induced Peripheral Neuropathy - Products under Development by Companies 16
Chemotherapy Induced Peripheral Neuropathy - Products under Investigation by Universities/Institutes 17
Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development 18
DARA BioSciences, Inc. 18
Eisai Co., Ltd. 19
Immune Pharmaceuticals, Ltd. 20
Laboratorios Del Dr. Esteve S.A. 21
MAKScientific, LLC 22
Mertiva AB 23
Paladin Labs Inc. 24
Panacea Pharmaceuticals, Inc. 25
PharmatrophiX, Inc. 26
Spectrum Pharmaceuticals, Inc. 27
Spinifex Pharmaceuticals Pty Limited 28
Virobay Inc. 29
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
(amitriptyline + ketamine hydrochloride) - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AK-295 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AL-309 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AM-1710 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
E-2072 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
E-52862 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
EMA-401 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Gene Therapy for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
KRN-5500 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
LM11A-31 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
PAN-811 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
PGN-703 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecule for Chemotherapy Induced Neuropathy - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
SPI-205 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
VBY-036 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Chemotherapy Induced Peripheral Neuropathy - Recent Pipeline Updates 61
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects 67
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products 68
Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones 69
Featured News & Press Releases 69
Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA 69
Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 69
Apr 10, 2012: EpiCept's AmiKet Receives Fast Track Designation From FDA 70
Mar 28, 2012: Allon Receives US Patent Covering Use Of Its Neuroprotective Technology Platform 71
Feb 07, 2012: EpiCept Files For AmiKet Fast Track Designation 71
Dec 23, 2011: EpiCept Receives FDA Permission To Initiate AmiKet Phase III Clinical Development 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74

List of Tables
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2015 9
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Chemotherapy Induced Peripheral Neuropathy - Pipeline by DARA BioSciences, Inc., H1 2015 18
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Eisai Co., Ltd., H1 2015 19
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals, Ltd., H1 2015 20
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2015 21
Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific, LLC, H1 2015 22
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mertiva AB, H1 2015 23
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Paladin Labs Inc., H1 2015 24
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals, Inc., H1 2015 25
Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX, Inc., H1 2015 26
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 27
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Spinifex Pharmaceuticals Pty Limited, H1 2015 28
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Virobay Inc., H1 2015 29
Assessment by Monotherapy Products, H1 2015 30
Assessment by Combination Products, H1 2015 31
Number of Products by Stage and Target, H1 2015 33
Number of Products by Stage and Mechanism of Action, H1 2015 35
Number of Products by Stage and Route of Administration, H1 2015 37
Number of Products by Stage and Molecule Type, H1 2015 39
Chemotherapy Induced Peripheral Neuropathy Therapeutics - Recent Pipeline Updates, H1 2015 61
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H1 2015 67
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H1 2015 68